MétaCan
Menu
Back to cohort

The ARAMIS trial - Allopurinol in patients with Refractory Angina to iMprove Ischemic Symptoms

2025· article· en· W7127922850 on OpenAlexaboutno aff
R Azevedo, S D V Ziotti, M S Rosal, T L V Pereira, F R Souza, M J N Alves, L O C Dourado, L A M Cesar, L H W Gowdak

Bibliographic record

VenueEuropean Heart Journal · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicParaoxonase enzyme and polymorphisms
Canadian institutionsnot available
Fundersnot available
KeywordsAllopurinolCoronary artery diseaseRevascularizationAnginaPlaceboRefractory (planetary science)Randomized controlled trialClinical trial

Abstract

fetched live from OpenAlex

Abstract Introduction Allopurinol has been considered as a therapeutic option for patients with coronary artery disease (CAD) who remain symptomatic despite optimisation of clinical treatment and with no more revascularization possibilities. The two main mechanisms explaining the potential benefit are the reduction of oxidative stress and improvement in endothelial function. However, the role of allopurinol in the management of patients with refractory angina remains unknown. Objectives To assess the efficacy and safety of allopurinol in improving exercise capacity in patients with refractory angina. Methods A prospective, randomized, placebo-controlled, double-blind study, including patients over 18 years of age with a diagnosis of stable angina, as classified by the Canadian Cardiovascular Society (CCS) grading of angina ≥ 2 for at least 3 months, secondary to obstructive CAD confirmed by invasive coronary angiography, taking at least three classes of antianginal drugs, and with documented ischemia. Patients were randomized to receive allopurinol 300 mg/day for 4 weeks, subsequently increased to 600 mg/day, or placebo, and were followed for 16 weeks. Clinical and laboratory assessments were performed at 0, 4, and 16 weeks, and patients were submitted to a cardiopulmonary exercise test at the start and at the end of the study follow up. Results A total of 41 patients were included, 22 in the allopurinol group and 19 in the placebo group. There was a predominance of male participants in the allopurinol group (86.4% vs. 47.4% in the placebo group, p = 0.007). There were no differences in other demographic data or clinical aspects between the two groups. No significant difference was observed between the two groups in the final total exercise time (591.1 seconds in the allopurinol group vs. 596.8 seconds in the placebo group; p = 0.990), nor in the metabolic parameters of the cardiopulmonary test. The allopurinol group showed a better final ischemic threshold, (531.1 seconds vs. 369.9 seconds; p = 0.027). In the clinical evaluation, there was a trend towards improvement in CCS functional classification (81.8% vs. 55.6%; p = 0.071) and a reduction in nitrate consumption (87.5% vs. 53.8%; p = 0,044) in the allopurinol group. Adverse events were rare, equally distributed between groups, of low severity, and did not require protocol interruption. Conclusion Allopurinol did not demonstrate an impact on improving exercise duration in cardiopulmonary exercise testing in patients with refractory angina. However, it was associated with a higher ischemic threshold, a reduction on use of short-acting nitrates and a trend towards improvement in angina functional CCS classification compared to placebo.Table 1 - Cardiopulmonary exercise test Table 2 - Clinical Data

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.398
Threshold uncertainty score0.358

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.246
Teacher spread0.239 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueEuropean Heart JournalSame topicParaoxonase enzyme and polymorphismsFrench-language works237,207